Production of myeloid dendritic cells (DC) pulsed with tumor-specific idiotype protein for vaccination of patients with multiple myeloma

References

• Steinman RM, Adams JC, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. IV. Identification and distribution in mouse spleen. J Exp Med 1975; 141: 804–20
   PubMedGoogle Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998; 392: 245–52
   PubMed Web of Science ®Google Scholar
• Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9: 271–96
   PubMed Web of Science ®Google Scholar
• Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996; 2: 52–8
   PubMed Web of Science ®Google Scholar
• Dzionek A, Inagaki Y, Okawa K, et al. Plasmacytoid dendritic cells: from specific surface markers to specific cellular functions. Hum Immunol 2002; 63: 1133–48
   PubMed Web of Science ®Google Scholar
• Small EJ, Fratesi P, Reese DM, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894–903
   PubMed Web of Science ®Google Scholar
• Rini B. Recent clinical development of dendritic cell-based immunotherapy for prostate cancer. Expert Opin Biol Ther 2004; 4: 1729–34
   PubMed Web of Science ®Google Scholar
• Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD8+ CTLs from naive precursors. J Immunol 1994; 153: 996–1003
   PubMedGoogle Scholar
• Mehta-Damani A, Markowicz S, Engleman EG. Generation of antigen-specific CD4+ T cell lines from naive precursors. Eur J Immunol 1995; 25: 1206–11
   PubMedGoogle Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994; 179: 1109–18
   PubMed Web of Science ®Google Scholar
• Suen Y, Lee SM, Aono F, et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy 2001; 3: 365–75
   PubMed Web of Science ®Google Scholar
• Yannelli JR, Sturgill J, Foody T, Hirschowitz E. The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC). Lung Cancer 2005; 47: 337–50
   PubMed Web of Science ®Google Scholar
• Elkord E, Williams PE, Kynaston H, Rowbottom AW. Human monocyte isolation methods influence cytokine production from in vitro generated dendritic cells. Immunology 2005; 114: 204–12
   PubMed Web of Science ®Google Scholar
• Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 1995; 182: 255–60
   PubMed Web of Science ®Google Scholar
• Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184: 465–72
   PubMed Web of Science ®Google Scholar
• Morse MA, Nair SK, Boczkowski D, et al. The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. Int J Gastrointest Cancer 2002; 32: 1–6
   PubMedGoogle Scholar
• Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Ann Surg 2002; 235: 540–9
   PubMed Web of Science ®Google Scholar
• Hess, PR, Boczkowski, D, Nair, SK, , et al. Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. Cancer Immunol Immunother 2005:1–12.
   Google Scholar
• Minami T, Nakanishi Y, Izumi M, et al. Enhancement of antigen-presenting capacity and antitumor immunity of dendritic cells pulsed with autologous tumor-derived RNA in mice. J Immunother 2003; 26: 420–31
   Google Scholar
• Schaft N, Dorrie J, Thumann P, et al. Generation of an optimized polyvalent monocyte-derived dendritic cell vaccine by transfecting defined RNAs after rather than before maturation. J Immunol 2005; 174: 3087–97
   PubMed Web of Science ®Google Scholar
• Koya RC, Weber JS, Kasahara N, et al. Making dendritic cells from the inside out: lentiviral vector-mediated gene delivery of granulocyte-macrophage colony-stimulating factor and interleukin 4 into CD14+ monocytes generates dendritic cells in vitro. Hum Gene Ther 2004; 15: 733–48
   PubMedGoogle Scholar
• Guan X, Peng J-R, Yaun L, et al. A novel, rapid strategy to form dendritomas from human dendritic cells and hepatocellular carcinoma cell line HCCLM3 cells using mature dendritic cells derived from human peripheral blood CD14+ monocytes within 48 hours of in vitro culture. World J Gastroenterol 2004; 10: 3564–8
   PubMedGoogle Scholar
• Obermaier B, Dauer M, Herten J, et al. Development of a new protocol for 2-day generation of mature dendritic cells from human monocytes. Biol Proced Online 2003; 5: 197–203
   PubMedGoogle Scholar
• Dauer M, Obermaier B, Herten J, et al. Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J Immunol 2003; 170: 4069–76
   PubMed Web of Science ®Google Scholar
• Wong EC, Lee SM, Hines K, et al. Development of a closed-system process for clinical-scale generation of DCs: evaluation of two monocyte-enrichment methods and two culture containers. Cytotherapy 2002; 4: 65–76
   PubMed Web of Science ®Google Scholar
• Pullarkat V, Lau R, Lee SM, et al. Large-scale monocyte enrichment coupled with a closed culture system for the generation of human dendritic cells. J Immunol Methods 2002; 267: 173–83
   PubMed Web of Science ®Google Scholar
• Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–26
   PubMed Web of Science ®Google Scholar
• Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma: a feasibility study. Blood 1999; 93: 2411–19
   PubMed Web of Science ®Google Scholar
• Liso A, Stockerl-Goldstein KE, Auffermann-Gretzinger S, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2000; 6: 621–7
   PubMed Web of Science ®Google Scholar
• Brown RD, Pope B, Murray A, et al. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood 2001; 98: 2992–8
   PubMed Web of Science ®Google Scholar
• Brown R, Murray A, Pope B, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol 2004; 125: 743–8
   PubMed Web of Science ®Google Scholar
• Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods 2003; 281: 65–78
   PubMed Web of Science ®Google Scholar
• Rubio V, Stuge TB, Singh N, et al. Ex vivo identification, isolation and analysis of tumor-cytolytic T cells. Nat Med 2003; 9: 1377–82
   PubMed Web of Science ®Google Scholar
• Guyre CA, Fisher JL, Waugh MG, et al. Advantages of hydrophobic culture bags over flasks for the generation of monocyte-derived dendritic cells for clinical applications. J Immunol Methods 2002; 262: 85–94
   PubMed Web of Science ®Google Scholar
• Anderson K. Moving disease biology from the laboratory to the clinic. Seminars Oncol 2002; 29: 17–20
   PubMed Web of Science ®Google Scholar
• Hideshima T, Richardson P, Anderson KC. New therapeutic approaches for multiple myeloma. Immunol Review 2003; 194: 164–76
   PubMed Web of Science ®Google Scholar